Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal into the CSF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MSC-NTF | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | BIOLOGICAL | - |
Inclusion Criteria: 1. Patient must fulfill El Escorial criteria (APPENDIX 2) for definite or probable ALS (sporadic and not familial) 2. Participants, either men or non pregnant women are between 20 and 75 years of age. 3. The patient is mentally intact and psychologically stable 4. Patients will ...
It is an investigational cell therapy being studied for amyotrophic lateral sclerosis (ALS). The treatment involves autologous mesenchymal bone marrow stromal cells that secrete neurotrophic factors, given through multiple intramuscular injections at 24 separate sites plus a single intrathecal injection into the cerebrospinal fluid.
It is being studied as a treatment for amyotrophic lateral sclerosis, a progressive neurological disease. The approach uses a patient's own bone marrow-derived mesenchymal stromal cells that secrete neurotrophic factors, delivered by intramuscular injections at 24 sites and one intrathecal injection into the cerebrospinal fluid.
Brainstorm Cell Therapeutics Inc., which trades under the ticker BCLI, is the developer of this autologous MSC-NTF cell therapy for amyotrophic lateral sclerosis. The company sponsored the Phase 2 study of the treatment.
It is in Phase 2 development. The single completed trial, NCT01777646, was a Phase 2 study that enrolled 14 patients with amyotrophic lateral sclerosis in Israel. It was an uncontrolled, non-randomized, open-label study, and no active trials are currently listed.
The trial is NCT01777646, titled Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS). It was a completed Phase 2 study that enrolled 14 participants aged 20 years and older in Israel, with no healthy volunteers included.
Yes. MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal into the CSF is also written as MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF. Both refer to the same autologous MSC-NTF cell therapy developed by Brainstorm Cell Therapeutics for ALS.